MarketCap
Facebook
X
Telegram
Tenax Therapeutics Accounts Receivables | TENX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 50.2 K | 72.6 K | 49.4 K | 36.4 K | 445 K | 13.4 K | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 445 K | 13.4 K | 111 K |
Quarterly Accounts Receivables Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.3 K | 39.3 K | 50.2 K | 50.2 K | 50.2 K | 50.2 K | 72.6 K | 72.6 K | 72.6 K | 72.6 K | 49.4 K | 49.4 K | 49.4 K | 49.4 K | 53.1 K | 36.4 K | 36.4 K | 36.4 K | 13.6 K | 64.8 K | 96.8 K | 445 K | 19.4 K | 17.2 K | 23.6 K | 13.4 K | - | 7.56 K | 28.1 K | 139 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 445 K | 7.56 K | 62 K |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sesen Bio
SESN
|
21 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
67 K | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
3 M | - | 57.95 % | $ 12.8 M | USA |
 |
Palatin Technologies
PTN
|
301 K | - | - | $ 13 M | USA |
 |
Brickell Biotech
BBI
|
1.13 M | - | -5.38 % | $ 6.06 M | USA |
 |
ESSA Pharma
EPIX
|
163 K | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
1.22 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
507 K | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
1.26 M | - | - | $ 5.78 B |  Niderland |
 |
Exicure
XCUR
|
11 K | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.82 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
2.02 M | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
1 K | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
1.52 M | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
8.84 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
3.68 M | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
5.94 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
29.3 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Incyte Corporation
INCY
|
1.02 B | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
1 K | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
3 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
2.05 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Catalyst Biosciences
CBIO
|
31.1 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
23.7 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
15.2 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
651 K | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
29.8 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
23.2 M | $ 10.12 | 0.4 % | $ 289 M | USA |